Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 25;32(5):251.
doi: 10.3390/curroncol32050251.

Molecular Prognostic Factors in Uterine Serous Carcinomas: A Systematic Review

Anna Svarna  1 , Michalis Liontos  1 , Alkistis Papatheodoridi  1 , Aristea-Maria Papanota  1 , Eleni Zografos  1 , Maria Kaparelou  1 , Flora Zagouri  1 , Meletios-Athanasios Dimopoulos  1
Affiliations

Molecular Prognostic Factors in Uterine Serous Carcinomas: A Systematic Review

Anna Svarna et al. Curr Oncol. .

Abstract

Uterine serous carcinomas are an aggressive minority of endometrial cancers. They are characterized by mutations in TP53 and extensive copy number alterations and are primarily classified in the copy number-high/p53abn molecular prognostic group, highlighting a unique molecular profile that is crucial for understanding their behavior and treatment responses. Clinical studies have shown that molecular categorization via biomarkers can facilitate proper treatment selection, and this is now widely used. In this context, the scope of this systematic review is to identify molecular characteristics with prognostic significance for these neoplasms to further inform on their treatment needs. We performed a comprehensive literature search of all articles written in English using the PubMed/Medline and Cochrane databases through February 2025. Our review led to the inclusion of 95 studies, from which we identified a total of 66 distinct molecular characteristics along with new cancer signatures that may impact prognosis. These findings have the potential to inform clinical practice by aiding in the development of tailored treatment strategies for patients with uterine serous carcinoma, ultimately improving outcomes in this challenging malignancy.

Keywords: biomarkers; prognostic factors; serous uterine cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Search strategy depicted in a PRISMA flow diagram. ** did not meet inclusion criteria.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Scarfone G., Secomandi R., Parazzini F., Vigano R., Mangili G., Frigerio L., Villa A., Tateo S., Ricci E., Bolis G. Clear cell and papillary serous endometrial carcinomas: Survival in a series of 128 cases. Arch. Gynecol. Obstet. 2013;287:351–356. doi: 10.1007/s00404-012-2586-x. - DOI - PubMed
    1. Huang C.Y., Tang Y.H., Chiang Y.C., Wang K.L., Fu H.C., Ke Y.M., Lau H.Y., Hsu K.F., Wu C.H., Cheng W.F. Impact of management on the prognosis of pure uterine papillary serous cancer—A Taiwanese Gynecologic Oncology Group (TGOG) study. Gynecol. Oncol. 2014;133:221–228. doi: 10.1016/j.ygyno.2014.02.010. - DOI - PubMed
    1. DeLair D.F., Burke K.A., Selenica P., Lim R.S., Scott S.N., Middha S., Mohanty A.S., Cheng D.T., Berger M.F., Soslow R.A., et al. The genetic landscape of endometrial clear cell carcinomas. J. Pathol. 2017;243:230–241. doi: 10.1002/path.4947. - DOI - PMC - PubMed
    1. Kandoth C., Schultz N., Cherniack A.D., Akbani R., Liu Y., Shen H., Robertson A.G., Pashtan I., Shen R., Benz C.C., et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73. doi: 10.1038/nature12113. - DOI - PMC - PubMed
    1. Berek J.S., Matias-Guiu X., Creutzberg C., Fotopoulou C., Gaffney D., Kehoe S., Lindemann K., Mutch D., Concin N. FIGO staging of endometrial cancer: 2023. J. Gynecol. Oncol. 2023;34:e85. doi: 10.3802/jgo.2023.34.e85. - DOI - PMC - PubMed

Publication types

Substances